$XBI $73.83 | -3.1%
Table of Contents:
Covid Updates
$MRNA -5.7% Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
$NVAX +1.8% FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine.
$MRNA -5.7% Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada.
Pipeline Updates
$ZSAN -2.1% Zosano Pharma Provides Corporate Update
$LYRA +5.6% Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022.
$RMLD +3.9% Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology.
$PRAX -5.7% Company’s Investigational New Drug application for the study of PRAX-222, an antisense oligonucleotide for the treatment of patients with SCN2A gain-of-function mutations, was placed on clinical hold.
$IONS -7.1% Ionis amends CARDIO-TTRansform study of eplontersen
$UTHR -1.0% United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference.
$KOD -0.5% Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences.
$ORPH -0.5% Orphazyme announces update on in-court restructuring proceedings.
$IPHA +6.3% First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca.
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$ABEO -7.1% Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock.
$ZYME +22.3% Zymeworks Confirms Receipt Of Unsolicited, Non-Binding Proposal From All Blue Falcons.
Posted by DV/JM
Comments